Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma

Video

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

Enrollment to this trial is still ongoing; it is about halfway there, Andorsky explains, and investigators are anticipating another 2 years of enrollment. Researchers will be investigating the durability of these responses; the median duration of response has not yet been reached. It is questionable whether it will go beyond 2 years. Because this is an immunotherapy, it is logical that these will be longer responses, he adds.

The other cohorts of this trial, which are comprised of marginal zone lymphoma and mantle cell lymphoma, are continuing to accrue, as well.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD